Court Rules on Patent Infringement by Product Yutrepia
2 reports, 2 independent
Updated Oct 5
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A court ruled that the product Yutrepia infringed on two valid claims of the '327 patent held by United Therapeutics. The ruling came shortly after Liquidia Corporation announced that its sales of Yutrepia totaled $300.3 million for the first six months of 2026. The court found that two of the six asserted patent claims were valid and infringed.
From prnewswire.com
Why it matters
The ruling raises the risk of various remedies, including the potential removal of Yutrepia's indication for PH-ILD. This development impacts the company's forecast of more than $1 billion in net revenue for 2027.
From prnewswire.com
Who's involved
- United TherapeuticsHolds the patent whose claims were found to have been infringed.
How it developed
Newest first. Tap a step to see who reported it.Court found Liquidia's product Yutrepia infringed on United Therapeutics' patent.1 source
Global settlement resolves six issues between the two companies.1 source
Keep exploring
The entities involved
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States